AJR ARRS: Your Link to CME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rhim, H.
Right arrow Articles by Choi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rhim, H.
Right arrow Articles by Choi, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.07.2384
AJR 2008; 190:91-98
© American Roentgen Ray Society


Original Research

Percutaneous Radiofrequency Ablation with Artificial Ascites for Hepatocellular Carcinoma in the Hepatic Dome: Initial Experience

Hyunchul Rhim1, Hyo K. Lim, Young-sun Kim and Dongil Choi

1 All authors: Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, Ilwon-Dong, Kangnam-Ku, Seoul 135-710, Korea.

Received April 7, 2007; accepted after revision June 24, 2007.

 
Address correspondence to H. K. Lim.

Supported by grant CRS105-14-1 from the 2005-2006 Samsung Medical Center Clinical Research Development Program.


Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
OBJECTIVE. Our objective was to assess the feasibility, safety, and efficacy of percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma (HCC) in the hepatic dome.

MATERIALS AND METHODS. Sonographically guided percutaneous radiofrequency ablation with artificial ascites was performed in 25 patients with 34 HCCs using an internally cooled electrode radiofrequency system. At least one hepatic dome tumor in each patient was considered difficult to treat percutaneously because of partially visible tumor (n = 16) or poor electrode path (n = 9) on planning sonography. We artificially induced ascites before radiofrequency ablation by dripping 5% dextrose in water (D/W) solution to improve tumor visibility or electrode path and to separate the radiofrequency ablation zone from the diaphragm. We assessed the technical feasibility, safety, and efficacy of this technique with clinical and CT follow-up for at least 4 months (mean, 281.4 days)

RESULTS. Artificial ascites was successfully achieved in 22 (88%) of 25 patients with the administration of a mean of 348 mL of D/W solution for an additional mean time of 9.3 minutes. There was substantial improvement in the visibility in 93.4% (15/16) of the partially visible tumors and in achieving a better path in 77.8% (7/9) of the tumors with a poor electrode path. The primary technique effectiveness rate for hepatic dome tumors was 96% (24/25) at 1-month follow-up CT. There was no diaphragmatic thermal injury in all but one case. No complication related to artificial ascites occurred during the follow-up period.

CONCLUSION. Percutaneous radiofrequency ablation with artificial ascites appears a feasible, safe, and effective technique for treating HCC of the hepatic dome.

Keywords: artificial ascites • complication • hepatocellular carcinoma • imaging-guided tumor ablation • radiofrequency ablation


Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Surgical resection is the only proven curative treatment of hepatocellular carcinoma (HCC). However, a majority of patients are unable to undergo surgical resection because of severely compromised liver function, advanced stage of tumors, or poor clinical condition [1]. Therefore, a number of imaging-guided tumor ablation techniques including chemical or thermal ablations have been introduced for the treatment of unresectable HCC [2-5]. Among various ablative therapies, radiofrequency ablation is most widely used because it produces more consistent local tumor control and good long-term results [6-10].

Imaging-guided tumor ablation can be performed via various approaches from the percutaneous route to open laparotomy. Most operators prefer the percutaneous approach, but it is not always possible depending on the characteristics of the index tumor. If the tumor is located high in the subcapsular portion of the hepatic dome, sonographically guided percutaneous radiofrequency ablation is technically challenging because of partial visibility of the tumor or a poor electrode path because of overlapped lungs or ribs, and there is risk of collateral thermal damage to the diaphragm [11-13].

Several technical measures have been suggested to solve this problem. They include different approaches (e.g., percutaneous transthoracic, laparoscopic, or open laparotomy) [14], different guiding techniques [15, 16], or artificial fluid into the pleural or peritoneal space [17-25]. However, to our best knowledge, there have been no large-series studies investigating the usefulness of artificial ascites in treating HCCs of the hepatic dome. The purpose of this study was to assess the feasibility, safety, and efficacy of sonographically guided percutaneous radiofrequency ablation with artificial ascites for HCC in the hepatic dome.


Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Our description of the radiofrequency ablation procedures and data assessment were based on the standardization of terms and reporting criteria proposed by the International Working Group on Image-Guided Tumor Ablation [26].


Figure 1
View larger version (111K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1 —Photograph of percutaneous radiofrequency ablation with artificial ascites. Note 6-French angiosheath inserted into perihepatic peritoneal space (arrow). Cool-tip RF is manufactured by Valleylab.

 
Patients
Between July 2005 and February 2006, a total of 262 patients with HCC were treated with sonographically guided percutaneous radiofrequency ablation in our institution. All patients met the following criteria for treatment with sonographically guided percutaneous radiofrequency ablation: a single nodular HCC ≤ 5 cm in maximum diameter, multinodular (up to three) HCCs ≤ 3 cm in maximum diameter each, absence of portal venous thrombosis, Child-Pugh class A or B liver cirrhosis, prothrombin time ratio > 50% (prothrombin time with international normalized ratio < 1.7), and a platelet count > 70,000 cells/mm3 (70 cells x 109/L). Among them, 25 patients with 34 nodular HCCs underwent radiofrequency ablation with assistance of artificial ascites because at least one tumor was inaccessible via the percutaneous approach because of the high location of the tumor. This study was approved by our institutional review board. Informed consent was obtained from all patients by one interventional radiologist who performed the procedure.

There were 18 men and seven women (age range, 48-81 years; mean, 62.5 years). Thirteen patients were considered not eligible for hepatic resection, and 12 patients voluntarily preferred radiofrequency ablation despite surgery also being feasible. All patients had liver cirrhosis as a result of hepatitis B (n = 18), hepatitis C (n = 5), hepatitis B and C (n = 1), or alcoholism (n = 1). At the time of the radiofrequency ablation, 21 patients had Child-Pugh class A cirrhosis and four had Child-Pugh class B cirrhosis. Fourteen patients underwent radiofrequency ablation with artificial ascites as a first-line treatment, whereas 11 patients had undergone surgery (n = 2), transarterial chemoembolization (TACE) (n = 6), radiofrequency ablation (n = 1), or combined treatment (n = 2) before radiofrequency ablation with artificial ascites.

A total of 25 patients had 34 tumors: a single tumor in 17 patients, two tumors in seven, and three tumors in one. The 25 tumors in the hepatic dome measured 1.0-3.0 cm at their maximum diameters (mean, 2.1 cm). The tumors in the hepatic dome were located at segment VIII in 13 patients, segment VII and VIII in four, segment VII in three, segment IV in four, and segment II in one. All 25 tumors in the hepatic dome were located at the subcapsular portion of each segment. The reasons that tumors were considered inaccessible via the percutaneous approach at sonography were that the tumor was only partially visible in 16 tumors and there was no adequate radiofrequency electrode path because of the lung parenchyma or costochondral junction in nine tumors (Table 1).


View this table:
[in this window]
[in a new window]

 
TABLE 1: Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma (HCC) in the Hepatic Dome Using Artificial Ascites in 25 Patients

 

The diagnosis of HCC was confirmed by percutaneous needle biopsy in three tumors of three patients. The remaining 31 tumors in 22 patients were considered to be HCC on the basis of characteristic imaging findings and an elevated serum tumor marker ({alpha}-fetoprotein > 400 mg/L) (n = 2) or satisfaction of at least two coincident radiologic findings that were compatible with HCC among CT, MRI, sonography, and angiography (n = 29) [27].

Induction of Artificial Ascites
We selected the peritoneal space under sonographic guidance with a 6-French angiosheath using the Seldinger technique. All procedures for induction of artificial ascites were performed by one interventional radiologist with 13 years of experience in sonographically guided intervention. For the tumor in the right lobe and segment IV right to the falciform ligament, we selected the right 7-8 intercostal space along the anterior axillary line. For the tumor in segments II and III, we selected the epigastric area.

After administering local anesthetic to the skin at the puncture site using 2% lidocaine, we inserted an 18-gauge sheathed needle just to the peritoneum. To effectively select the peritoneal space, we instructed the patient to slightly inhale downward to displace the level of the liver parenchyma and to breath-hold. Then we advanced the sheath needle into the subcapsular portion of the liver parenchyma. After removal of the inner stylet of the sheath needle, we instructed the patient to fully exhale and breath-hold again. At this moment, the tip of the sheath usually remained in the peritoneal space because of its retraction from upward-displaced hepatic parenchyma with full expiration. At this moment, we quickly inserted a 0.035-inch guidewire through the sheath and checked by sonography whether the wire was located in the peritoneal space. Finally, we placed a 6-French angiosheath over the guidewire.

After placement of the angiosheath into the peritoneal space, we opened a three-way stopcock at the side arm of the angiosheath. This stopcock was connected to 1,000 mL of 5% dextrose in water (D/W) solution at room temperature. We did not try any position change of the patient to collect the infused fluid at the desired portion. If the entire boundary of the index tumor could be visualized and a safe radiofrequency electrode path could be achieved by downward displacement of the liver with sonographic monitoring, we considered the induction of artificial ascites technically successful. We then performed the conventional radiofrequency ablation procedure (Fig. 1).

Radiofrequency Ablation
All radiofrequency ablation procedures were also performed on an inpatient basis by the same interventional radiologist with 9 years of experience in radiofrequency ablation. We used internally cooled electrodes and a 200-W generator (Cool-tip, Valleylab). All the patients were treated under IV conscious sedation and local anesthesia. Our therapeutic strategy of radiofrequency ablation was to include a peripheral margin of at least 0.5 mm of normal hepatic parenchyma surrounding the tumor and the entire tumor itself. Depending on tumor size and electrode type, we performed a total of 28 sessions in 25 patients (1 or 2 sessions per patient; mean, 1.12) with single or multiple overlapping ablations (1-4 overlapping ablations; mean, 1.8). We used a single (3-cm active tip) electrode in 33 of 34 tumors and a cluster electrode in one tumor. We cauterized the electrode path during retraction of the electrode to minimize bleeding after ablation. We did not aspirate or drain the infused artificial ascites after the ablation procedure.

Follow-Up After Ablation
For the early evaluation of the therapeutic response, we performed contrast-enhanced CT immediately after radiofrequency ablation. Postprocedural CT examinations were performed immediately (within 4 hours) with one of two helical scanners (HiSpeed or LightSpeed QX/i, GE Healthcare). The axial images were obtained before and at 30, 60-70, and 180 seconds after IV contrast material injection. Coronal and sagittal reformatted images were also obtained. The radiologist who performed the radiofrequency ablation procedure also evaluated the therapeutic response and any immediate complications including hemoperitoneum and diaphragmatic thermal injury.

All the patients underwent a follow-up four-phase CT 1 month after radiofrequency ablation. Residual tumors were defined as irregular peripheral-enhancing foci in the ablation zone at contrast-enhanced follow-up CT, immediately or 1 month after radiofrequency ablation. In cases of complete ablation of the tumor with no appearance of a new tumor in other sites of the liver at 1-month follow-up CT, subsequent CT examinations were repeated every 2-4 months as part of our follow-up protocol.

Assessment of Technical Feasibility and Safety of Artificial Ascites
To evaluate the technical feasibility of artificial ascites, we recorded how many needle punctures were required to select the peritoneal space, time for selection of the peritoneal space (from skin anesthesia to placement of the angiosheath into the peritoneal space), time for successful induction of artificial ascites, total amount of artificial ascites infused, and maximum distance between the peritoneum and hepatic capsule at sonography. We also assessed whether artificial ascites improved the visibility of the index tumor or radiofrequency electrode path and technical problems in the induction of artificial ascites.

To assess the safety related to artificial ascites, we evaluated whether the artificial ascites was shifted into the pleural space and measured the Hounsfield units of the artificial ascites around the radiofrequency ablation zone on the immediate CT to evaluate whether artificial ascites may have a role in the development of hemoperitoneum after radiofrequency ablation. In addition, abdominal sonography was performed to evaluate whether artificial ascites remained and caused any intermediate complication at 1 week after the procedure in the initial seven patients. Delayed complications related to artificial ascites were assessed with a follow-up four-phase CT 1 month after radiofrequency ablation and then at every 2-4 months for at least 6 months. Complications were assigned to major and minor categories [27].

Assessment of Diaphragmatic Injury and Therapeutic Effectiveness
To assess the protective effect of artificial ascites, we evaluated whether the diaphragm adjacent to the radiofrequency ablation zone in the hepatic dome showed any evidence of swelling at immediate follow-up CT compared with pretreatment CT or whether any patient complained of sustained shoulder pain during the follow-up period.

To assess the therapeutic efficacy of ablation, we evaluated the primary (technique) effectiveness in terms of residual tumor with 1-month follow-up CT. Local tumor progression was determined when a subsequent follow-up CT showed any growing and enhancing tumor in the ablation zone where there had been complete primary effectiveness (i.e., no evidence of residual tumor) for at least 6 months. Evaluation of secondary (technique) effectiveness or survival analysis was beyond the scope of the current study.

Statistical Analysis
Data analyses in calculating the mean and median value of measurement were performed with commercially available software (Excel 2000, Microsoft).


Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Technical Feasibility and Efficacy of Artificial Ascites
Placement of the angiosheath into the perihepatic space was successful in all 25 patients. However, induction of artificial ascites was technically successful in 22 (88%) of the 25 patients. There was substantial improvement in the visibility at shallow respiration in 93.4% (15/16) of the partially visible tumors and in achieving a better electrode path in 77.8% (7/9) of the tumors in which the electrode path was poor (Figs. 2A, 2B, 2C, 2D, 2E, 2F, 2G, 2H, 2I and 3A, 3B, 3C, 3D, 3E). Three tumors showed technical failure: two in segment VII and one in segment IV. In addition, the two patients with tumor in segment VII had a history of surgical resection or TACE before radiofrequency ablation with artificial ascites (Fig. 4A, 4B, 4C, 4D, 4E).


Figure 2
View larger version (76K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2A —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse contrast-enhanced CT scan before radiofrequency ablation shows hyperattenuating 1.0-cm nodule in liver segment VIII (arrow).

 

Figure 3
View larger version (115K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2B —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Intercostal oblique image at planning sonography shows subtle hypoechoic nodule only on deep inhalation (arrow).

 

Figure 4
View larger version (92K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2C —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Sonogram shows perihepatic artificial ascites (arrow) introduced via 6-French angiosheath (arrowhead).

 

Figure 5
View larger version (86K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2D —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Sonogram shows index tumor (arrow) more clearly, even on shallow breathing.

 

Figure 6
View larger version (89K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2E —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Sonogram shows targeting phase of procedure. Note radiofrequency electrode in index tumor (arrow).

 

Figure 7
View larger version (74K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2F —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Sonogram shows monitoring phase of procedure. Note hyperechoic radiofrequency ablation zone during ablation (arrow).

 

Figure 8
View larger version (116K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2G —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse contrast-enhanced CT scan obtained immediately after radiofrequency ablation shows nonenhancing radiofrequency ablation zone encompassing tumor (arrow). There is no evidence of collateral thermal damage to diaphragm.

 

Figure 9
View larger version (115K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2H —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse contrast-enhanced CT scan obtained at 1 month after radiofrequency ablation shows complete ablation without local tumor progression. Artificial ascites is completely absorbed without any complication.

 

Figure 10
View larger version (130K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2I —48-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse contrast-enhanced CT scan obtained at 9 months after radiofrequency ablation shows complete ablation without local tumor progression.

 

Figure 11
View larger version (83K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3A —69-year-old woman with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse contrast-enhanced CT scan before radiofrequency ablation shows hyperattenuating, 2-cm nodule in liver segment VIII (arrow).

 

Figure 12
View larger version (89K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3B —69-year-old woman with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse (B) and coronal (C) contrast-enhanced CT scans obtained immediately after radiofrequency ablation show nonenhancing radiofrequency ablation zone encompassing tumor (arrow). There is no evidence of collateral thermal damage of diaphragm. Note minimal shifting of artificial ascites (asterisk) into pleural cavity (arrowhead, B).

 

Figure 13
View larger version (107K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3C —69-year-old woman with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse (B) and coronal (C) contrast-enhanced CT scans obtained immediately after radiofrequency ablation show nonenhancing radiofrequency ablation zone encompassing tumor (arrow). There is no evidence of collateral thermal damage of diaphragm. Note minimal shifting of artificial ascites (asterisk) into pleural cavity (arrowhead, B).

 

Figure 14
View larger version (85K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3D —69-year-old woman with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse contrast-enhanced CT scan obtained at 1 month after radiofrequency ablation shows complete ablation without local tumor progression. Artificial ascites is completely absorbed without any complication.

 

Figure 15
View larger version (97K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3E —69-year-old woman with hepatocellular carcinoma in right hepatic dome (segment VIII). Transverse contrast-enhanced CT scan obtained at 7 months after radiofrequency ablation shows complete ablation without local tumor progression.

 

Figure 16
View larger version (113K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4A —63-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Patient has history of segment VII segmentectomy, radiofrequency ablation, and transarterial chemoembolization. Transverse contrast-enhanced CT scan before radiofrequency ablation shows partially lipolyzed nodule in liver segment VII (arrow).

 

Figure 17
View larger version (88K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4B —63-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Patient has history of segment VII segmentectomy, radiofrequency ablation, and transarterial chemoembolization. Intercostal oblique scan at planning sonography shows 2.5-cm hypoechoic nodule (arrow). However, there is no adequate radiofrequency electrode path because of overlapped costochondral junction.

 

Figure 18
View larger version (81K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4C —63-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Patient has history of segment VII segmentectomy, radiofrequency ablation, and transarterial chemoembolization. Sonogram shows perihepatic artificial ascites (arrow) around anterior perihepatic area. No fluid is accumulated around liver capsule bearing index tumor probably because of postoperative adhesions (arrowheads).

 

Figure 19
View larger version (124K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4D —63-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Patient has history of segment VII segmentectomy, radiofrequency ablation, and transarterial chemoembolization. Transverse (D) and coronal (E) contrast-enhanced CT scans obtained immediately after radiofrequency ablation show nonenhancing radiofrequency ablation zone (arrow) encompassing tumor. However, there is moderate thickening of diaphragm adjacent to radiofrequency ablation zone. Patient complained of right shoulder pain for 4 days after ablation.

 

Figure 20
View larger version (97K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4E —63-year-old man with hepatocellular carcinoma in right hepatic dome (segment VIII). Patient has history of segment VII segmentectomy, radiofrequency ablation, and transarterial chemoembolization. Transverse (D) and coronal (E) contrast-enhanced CT scans obtained immediately after radiofrequency ablation show nonenhancing radiofrequency ablation zone (arrow) encompassing tumor. However, there is moderate thickening of diaphragm adjacent to radiofrequency ablation zone. Patient complained of right shoulder pain for 4 days after ablation.

 
The technical details of each patient are summarized in Table 1. The number of needle punctures of the hepatic parenchyma ranged from one to three (mean, 1.2). The time for placement of the angiosheath ranged from 2 minutes 5 seconds to 11 minutes (mean, 3 minutes 58 seconds). The time required for successful induction of artificial ascites in 24 patients ranged from 3 minutes 20 seconds to 20 minutes (mean, 9 minutes 20 seconds). The amount of solution for induction of artificial ascites ranged from 100 to 1,000 mL (mean, 348 mL). The maximum distance between the peritoneum and hepatic capsule ranged from 3 to 20 mm (mean, 15 mm).

Safety of Artificial Ascites
The artificial ascites was partially shifted into the right pleural space in 14 of 25 patients at immediate follow-up CT. The attenuation of artificial ascites around the radiofrequency ablation zone ranged from -8 to 28 H (mean, 12.7 H). No patients showed abnormal vital signs and decreasing hemoglobin levels until the day after the procedure. The artificial ascites in six of seven patients who underwent 1-week follow-up sonography had completely disappeared, and a minimal amount of ascites was noted in the perihepatic space in one patient with no irritating peritoneal signs. All patients showed complete absorption of artificial ascites and the shifted pleural effusion at 1-month follow-up CT. No patients showed any clinical signs of delayed complications such as hemoperitoneum or peritonitis during follow-up of at least 4 months.

Diaphragmatic Injury and Therapeutic Effectiveness
One patient with technical failure of artificial ascites because of postoperative adhesions showed reversible thermal injury of the diaphragm (Fig. 4A, 4B, 4C, 4D, 4E). The remaining 24 patients did not show diaphragmatic swelling at immediate follow-up CT, and none complained of sustained shoulder pain. The primary technique effectiveness was 96% (24/25) at 1-month follow-up CT. On the basis of tumor in the hepatic dome, the rate of local tumor progression was 16% (4/25). On the patient basis, the rate of new recurrent tumors was 36% (9/25).


Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
In spite of many previous investigations regarding percutaneous thermal ablation for tumors in the hepatic dome [17-24, 28-31], clinical studies using artificial ascites have been relatively limited, with only small (< 10 patients) series [17-19, 21, 31]. Our study showed that percutaneous induction of artificial ascites is technically feasible and effective in improving both tumor visibility and the radiofrequency electrode path in radiofrequency ablation for HCC at the hepatic dome. This technique may allow us to avoid more invasive (e.g., open surgical) or time-consuming (e.g., CT guidance) approaches and to minimize thermal injury of the diaphragm with reasonable time and cost.

Regarding the techniques for induction of artificial ascites, Raman et al. [24] in an experimental model used an 18-gauge Chiba needle for insertion into the pocket of lidocaine at the plane between the peritoneum and the liver capsule. This method seems to be the most popular technique for induction of artificial ascites. However, during the procedure an operator should monitor closely whether the tip of the needle is located in the peritoneal space. Our technique using the angiosheath may provide rapid induction of artificial ascites because of the larger bore of the route without the necessity of monitoring the tip of the needle during the ablation.

Our study also showed that induction of artificial ascites is a safe procedure. Traditionally, the ascitic fluid was thought to wash away thrombogenic material at the puncture site and decrease or eliminate the "tamponade effect" from the opposing parietal peritoneum against the liver [24, 32]. However, in our study, there was no case of complication related to artificial ascites, such as hemoperitoneum. This may result from coagulation of the electrode path during removal of the electrode. Furthermore, based on our results, we now doubt whether ascites should be regarded as a relative contraindication for percutaneous radiofrequency ablation in patients with correctable coagulopathy [33].

The main limitation of artificial ascites appears to be peritoneal adhesions due to previous treatments (surgical resection, TACE, or thermal ablation) and the tumor in the bare area of liver [24, 34]. In our results, two of three cases with technical failure had a history of previous surgery located in segment VII. Therefore, an operator should keep in mind that these two factors can be a cause of technical failure for induction of artificial ascites and consider an alternative approach or treatment.

Many studies have reported on improving the sonic window using artificial pleural effusion [10, 20, 21]. Minami et al. [20] and Koda et al. [10] reported the feasibility and safety of artificial pleural effusion in radiofrequency ablation for HCC in the hepatic dome. Both studies reported a high local control rate of 92-96% with the assistance of artificial pleural effusion. The adverse effect was minimal, including mild cough and dyspnea in some patients. Toyoda et al. [15] and Shibata et al. [16] reported CT-guided transpulmonary radiofrequency ablation without any artificial fluid. Complete ablation was achieved in most cases, but there were major complications including major pneumothorax and pleural effusion in 29-45% of cases [15, 16, 28].

The rate of local tumor progression in the current study seems to be somewhat higher than that of previous reports for small HCC. We can assume that a slightly higher rate of local tumor progression may have several reasons: the possible heat sink effect of artificial ascites, difficulty in accurate placement of the electrode in the small hepatic nodule floating in the artificial ascites, and some effect of a learning curve period. We may decrease the rate of local tumor progression using artificial hydrothorax, but we need to trade-off substantial thoracic complications. However, we believe that sonographically guided radiofrequency ablation using artificial fluid is a safer procedure and has the clear advantage of separating the radiofrequency ablation zone from the abutting dangerous organs, including the diaphragm and gastrointestinal tract, compared with sonographically guided or CT-guided radiofrequency ablation with artificial pleural effusion.

Recently, Laeseke et al. [30] investigated the characteristics and usefulness of artificial fluid. They showed instillation of 5% D/W into the peritoneal cavity before hepatic radiofrequency ablation decreases the risk and severity of diaphragm injuries compared with no pretreatment or pretreatment with 0.9% saline in a swine model. Because of its isomolarity and nonionic composition, 5% D/W is a nearly ideal protective buffer to infuse into the abdomen before thermal ablation [30]. In another study, the authors also reported pretreatment with intraperitoneal 5% D/W before radiofrequency ablation of peripheral liver tumors in 10 patients decreased pain, narcotic use, and length of hospital stay compared with 10 control patients [31].

This study has several inherent limitations. First, we could not evaluate the true benefit of artificial ascites in allowing successful percutaneous ablation and minimizing thermal injury of the diaphragm because we could not perform a randomized controlled study with a control group. Second, because of the small number of our subjects and because of the short-term follow-up, we do not know whether artificial ascites increases the possibility of hemoperitoneum in a patient with significant coagulopathy or delayed needle track seeding. Third, in this study, we could not find more subjective criteria for assessing the outcome regarding tumor visibility and radiofrequency electrode path. More subjective criteria will be necessary when the controlled trials are performed. Finally, our study was limited to those tumors that were partially visualized at sonography whereas the application of artificial ascites for those sonographically invisible tumors is ongoing in our institution.

In summary, we performed percutaneous radiofrequency ablation with artificial ascites for HCC in the hepatic dome, which has been considered a difficult procedure to perform percutaneously because of a poor sonic window or radiofrequency electrode path. We have proven that artificial ascites can improve the radiofrequency electrode path by downward displacement of the hepatic parenchyma and separate the radiofrequency ablation zone from the diaphragm. Thus, sonographically guided percutaneous radiofrequency ablation with artificial ascites appears a feasible, safe, and effective technique for treating HCC of the hepatic dome.


Acknowledgments
 
We thank Jung Hwan Han, Hyun Ja Jee, and Kyong Mee Lee at Samsung Biomedical Research Institute for assistance in procedure and data collection.


References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 

  1. Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004;127 [5 suppl 1]:S248 -S260[Medline]
  2. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol 2005; 31:331 -347[CrossRef][Medline]
  3. Dodd GD 3rd, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. RadioGraphics 2000;20 : 9-27[Abstract/Free Full Text]
  4. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129 : 122-130[CrossRef][Medline]
  5. McGhan JP, Dodd GD 3rd. Radiofrequency ablation of the liver: current status. AJR 2001;176 : 3-16[Free Full Text]
  6. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228 : 235-240[Abstract/Free Full Text]
  7. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < 4 cm. Gastroenterology2004; 127:1714 -1723[CrossRef][Medline]
  8. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology2005; 234:961 -967[Abstract/Free Full Text]
  9. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 2005;103 : 1201-1209[CrossRef][Medline]
  10. Koda M, Ueki M, Maeda Y, et al. Percutaneous sonographically guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma located under the diaphragm. AJR2004; 183:583 -588[Abstract/Free Full Text]
  11. Rhim H, Dodd GD 3rd, Chintapalli KN, et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. RadioGraphics 2004;24 : 41-52[Abstract/Free Full Text]
  12. Koda M, Ueki M, Murawaki Y. Diaphragmatic perforation and hernia after hepatic radiofrequency ablation. AJR2003; 180:1561 -1562[Free Full Text]
  13. Kim YS, Rhim H, Sung JH. Bronchobiliary fistula after radiofrequency thermal ablation of hepatic tumor. J Vasc Interv Radiol 2005; 16:407 -410[Medline]
  14. Machi J, Uchida S, Sumida K, et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg2001; 5:477 -489[CrossRef][Medline]
  15. Toyoda M, Kakizaki S, Horiuchi K, et al. Computed tomography-guided transpulmonary radiofrequency ablation for hepatocellular carcinoma located in hepatic dome. World J Gastroenterol 2006;12 : 608-611[Medline]
  16. Shibata T, Shibata T, Maetani Y, et al. Transthoracic percutaneous radiofrequency ablation for liver tumors in the hepatic dome. J Vasc Interv Radiol 2004; 15:1323 -1327[CrossRef][Medline]
  17. Ohmoto J, Tsuzuki M, Yamamoto S. Percutaneous microwave coagulation therapy with intraperitoneal saline infusion for hepatocellular carcinoma in the hepatic dome. AJR 1999;172 : 65-66[Free Full Text]
  18. Ohmoto J, Yamamoto S. Percutaneous microwave coagulation therapy using artificial ascites. AJR 2001;176 : 817-818[Free Full Text]
  19. Kapoor BS, Hunter DW. Injection of subphrenic saline during radiofrequency ablation to minimize diaphragmatic injury. Cardiovasc Intervent Radiol 2003;26 : 302-304[CrossRef][Medline]
  20. Minami Y, Kudo M, Kawasaki T, et al. Percutaneous ultrasound-guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. J Gastroenterol2003; 38:1066 -1070[CrossRef][Medline]
  21. Shibata T, Iimuro Y, Ikai I, Hatano E, Yamaoka Y, Konishi J. Percutaneous radiofrequency ablation therapy after intrathoracic saline solution infusion for liver tumor in the hepatic dome. J Vasc Interv Radiol 2002; 13:313 -315[Medline]
  22. Lee YR, Rhim H, Kim YS, et al. Intraperitoneal saline infusion during radiofrequency ablation of subcapsular hepatic tumor. J Vasc Interv Radiol 2005; 16:753 -754[CrossRef][Medline]
  23. Raman SS, Aziz D, Chang X, Sayre J, Lassman C, Lu D. Minimizing diaphragmatic injury during radiofrequency ablation: efficacy of intraabdominal carbon dioxide insufflation. AJR2004; 183:197 -200[Abstract/Free Full Text]
  24. Raman SS, Ku DS, Vodopich DJ, Sayre J, Lassman C. Minimizing diaphragmatic injury during radiofrequency ablation: efficacy of subphrenic peritoneal saline injection in a porcine model. Radiology 2002;222 : 819-823[Abstract/Free Full Text]
  25. Kondo Y, Yoshida H, Shiina S, Tateishi R, Teratani T, Omata M. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg 2006; 93:1277 -1282[CrossRef][Medline]
  26. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005;235 : 728-739[Abstract/Free Full Text]
  27. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference—European Association for the Study of the Liver. J Hepatol 2001; 35:421 -430[CrossRef][Medline]
  28. de Baere T, Dromain C, Lapeyre M, et al. Artificially induced pneumothorax for percutaneous transthoracic radiofrequency ablation of tumors in the hepatic dome: initial experience. Radiology2005; 236:666 -670[Abstract/Free Full Text]
  29. Kim YS, Rhim H, Paik SS. Radiofrequency ablation of the liver in a rabbit model: creation of artificial ascites to minimize collateral thermal injury to the diaphragm and stomach. J Vasc Interv Radiol 2006; 17:541 -547[CrossRef][Medline]
  30. Laeseke PF, Sampson LA, Brace CL, Winter TC 3rd, Fine JP, Lee FT Jr. Unintended thermal injuries from radiofrequency ablation: protection with 5% dextrose in water. AJR 2006;186 [5 suppl]:S249 -S254[Abstract/Free Full Text]
  31. Hinshaw JL, Laeseke PF, Winter TC 3rd, Kliewer MA, Fine JP, Lee FT Jr. Radiofrequency ablation of peripheral liver tumors: intraperitoneal 5% dextrose in water decreases postprocedural pain. AJR2006; 186[5 suppl]:S306 -S310[Abstract/Free Full Text]
  32. Perrault J, McGill D, Ott BJ, Talor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology1978; 74:103 -106[Medline]
  33. Murphy FB, Barefield KP, Steinberg HV, Bernardino ME. CT- or sonography-guided biopsy of the liver in the presence of ascites: frequency of complications. AJR 1988;151 : 485-486[Abstract/Free Full Text]
  34. Miele V, Andreoli C, De Cicco ML, Adami L, David V. Hemoretroperitoneum associated with liver bare area injuries: CT evaluation. Eur Radiol 2002;12 : 765-769[CrossRef][Medline]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
J. Cha, H. Rhim, J. Y. Lee, Y.-s. Kim, D. Choi, M. W. Lee, W. J. Lee, and H. K. Lim
Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: Assessment of Safety in Patients With Ascites
Am. J. Roentgenol., November 1, 2009; 193(5): W424 - W429.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
M W LEE, Y J KIM, S W PARK, J H HWANG, S I JUNG, H J JEON, and W K KWON
Percutaneous radiofrequency ablation of small hepatocellular carcinoma invisible on both ultrasonography and unenhanced CT: a preliminary study of combined treatment with transarterial chemoembolisation
Br. J. Radiol., November 1, 2009; 82(983): 908 - 915.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
S. Lee, H. Rhim, Y.-S. Kim, D. Choi, W. J. Lee, H. K. Lim, and B. Shin
Percutaneous Radiofrequency Ablation of Hepatocellular Carcinomas: Factors Related to Intraprocedural and Postprocedural Pain
Am. J. Roentgenol., April 1, 2009; 192(4): 1064 - 1070.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rhim, H.
Right arrow Articles by Choi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rhim, H.
Right arrow Articles by Choi, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS